|
|
Prohost Biotechnology OnlineThe Newsletter of Biotechnology Research and Investment |
|
|
|
ORCHID: CASHING IN ON THE COMPLETION OF A MILESTONENDReg1Date: 20 Mar 2008 Commentshttp://www.welivetogether.com/main.htm?id=chikenn http://www.bangbrosnetwork.com/t1/revs=milfreg/ http://www.asstraffic.com/go/485861/1/9/n/ http://www.allinternal.com/go/485861/2/9/n/ http://www.cumfiesta.com/main.htm?id=chikenn http://www.captainstabbin.com/main.htm?id=chikenn http://www.bignaturals.com/main.htm?id=chikenn http://www.milfhunter.com/main.htm?id=chikenn Date: 29 Jun 2001 CommentsPRINCETON, N.J., June 29, 2001 – Orchid BioSciences, Inc. (Nasdaq: ORCH) today announced that it has successfully completed the first milestone in its multi-year genotyping and pharmacogenetics collaboration with AstraZeneca, resulting in a significant payment to Orchid. Further financial details were not disclosed. Using the SNPcode™ technology that combines Orchid’s proprietary SNP-IT™ biochemistries with the GenFlex™ chip and GeneChipŇ system of Affymetrix, Orchid rapidly developed assays and conducted genotyping for the first cohort of samples provided by AstraZeneca. Exceeding the Targets In a significant concordance study to validate the overall accuracy and reproducibility of the technology, Orchid has also exceeded all of the targets established for the first phase of the program. Based on these positive results, Orchid and AstraZeneca are now proceeding to the next phase of the collaboration. "We are very pleased to have rapidly reached the first delivery milestone in our collaboration with AstraZeneca," said Jack T. Ball, Jr., senior vice president and general manager of Orchid’s Life Sciences Group. "We are achieving outstanding accuracy and throughput on the high throughput SNPcode platform that we recently added to our MegaSNPatron™ genotyping facility, and these results are further confirmation of the exceptional performance of this system." The SNPcode system is particularly well suited for analyzing large numbers of SNPs for whole chromosome and genome wide mapping studies. Orchid is using SNPcode to develop a SNP map containing several thousand widely spaced SNPs across the human genome and plans to use this approach to develop panels of SNPs that affect critical pharmacogenetic parameters like drug metabolism, distribution and excretion (so called "ADME" panels). "We are very happy with the quality of the data that Orchid has delivered in the first phase of this effort as well as the overall spirit of the collaboration," said Dr. Rakesh Anand, director of R&D genetics, enabling science and technology of AstraZeneca. "We look forward to this collaboration continuing to provide valuable genetic data that will contribute to our pharmacogenetics research." This project milestone is the first in a multi-year SNP scoring and pharmacogenetic collaboration between Orchid and AstraZeneca announced in February 2001. The collaboration includes the design and development of SNP panels and assays for a variety of disease areas and analyses to support pharmacogenetics studies. ABOUT ORCHID Orchid BioSciences, Inc. is a leading provider of products, services and technologies for SNP scoring and genetic diversity analyses. Orchid has developed SNP-IT, its proprietary SNP analysis technology and markets SNPstreamŇ instruments and SNPware™ consumables that rapidly generate highly accurate, cost effective SNP information. SNP-IT is usable in environments ranging from small-scale laboratories to large commercial facilities. Its versatility also has enabled Orchid to partner with industry leaders to make SNP-IT-enabled products available on a wide variety of instrument platforms as part of its Platform Propagation™ strategy. Orchid provides high throughput SNP scoring services to pharmaceutical, biotechnology and academic customers through its MegaSNPatron facilities and DNA and pharmacogenetic testing services through its accredited GeneScreen and Cellmark facilities that conduct paternity and forensics testing, as well as clinical quality genotyping. Orchid also provides content-rich SNP databases and SNP panels to its customers and collaborators. Through its Pharmaceutical Value Creation™ business, Orchid also seeks to identify proprietary medical applications of SNPs. More information on Orchid can be found at its web site www.orchid.com.
| ||||||||
|
